Search

Your search keyword '"Rongioletti, F"' showing total 1,236 results
Start Over Author "Rongioletti, F"
1,236 results on '"Rongioletti, F"'

1. Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study

Author

Campanati, A., Bianchelli, T., Gesuita, R., Foti, C., Malara, G., Micali, G., Amerio, P., Rongioletti, F., Corazza, M., Patrizi, A., Peris, K., Pimpinelli, N., Parodi, A., Fargnoli, M. C., Cannavo, S. P., Pigatto, P., Pellacani, G., Ferrucci, S. M., Argenziano, G., Cusano, F., Fabbrocini, G., Stingeni, L., Potenza, M. C., Romanelli, M., Bianchi, L., and Offidani, A.

Published
2022
Full Text
View/download PDF

3. Correction to: Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study

Author

Campanati, A., Bianchelli, T., Gesuita, R., Foti, C., Malara, G., Micali, G., Amerio, P., Rongioletti, F., Corazza, M., Patrizi, A., Peris, K., Pimpinelli, N., Parodi, A., Fargnoli, M. C., Cannavo, S. P., Pigatto, P., Pellacani, G., Ferrucci, S. M., Argenziano, G., Cusano, F., Fabbrocini, G., Stingeni, L., Potenza, M. C., Romanelli, M., Bianchi, L., and Offidani, A.

Published
2022
Full Text
View/download PDF

4. Arrhythmias and other cardiovascular diseases in young patients (<40 years) with moderate/severe atopic dermatitis: A multicentric study in northern Italy

Author

Paolino, G, Carugno, A, Frontera, A, Rongioletti, F, Malagoli, P, Foti, A, Brianti, P, Guida, S, Germiniasi, F, Bianchi, V, Raponi, F, Sena, P, Narcisi, A, Costanzo, A, Mercuri, S, Valenti, M, Bianchi, V G, Mercuri, S R, Paolino, G, Carugno, A, Frontera, A, Rongioletti, F, Malagoli, P, Foti, A, Brianti, P, Guida, S, Germiniasi, F, Bianchi, V, Raponi, F, Sena, P, Narcisi, A, Costanzo, A, Mercuri, S, Valenti, M, Bianchi, V G, and Mercuri, S R

Published
2024

5. Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma

Author

Paolino, G, Carugno, A, Rongioletti, F, Ponzoni, M, Russo, V, Sena, P, Ardigò, M, Costanzo, A, Mercuri, S, Valenti, M, Mercuri, SR, Paolino, G, Carugno, A, Rongioletti, F, Ponzoni, M, Russo, V, Sena, P, Ardigò, M, Costanzo, A, Mercuri, S, Valenti, M, and Mercuri, SR

Abstract

The occurrence of bone marrow metastases (BMM) in melanoma patients is often underestimated, with only 7% detected during in-vivo staging procedures but rising to 45% in autopsy cases. This systematic review aims to shed light on the clinical and laboratory features of BMM in melanoma by analyzing 73 studies selected from 2 482 initially retrieved from PubMed, Embase, and Cochrane CENTRAL databases. Our findings reveal a slight male predominance, with a median age at BMM diagnosis of 56 years. Primary melanoma sites included the skin (52%), mucosa (8.8%), uvea (20.5%) and unidentified (19%). BMM was preceded by lymph node involvement in 36.5% of cases, whereas 63% showed no nodal metastases, with direct BMM occurring in 22.5% and metastases to other sites in 41%. Common BMM symptoms included pain (60.7%), anemia (80%), thrombocytopenia, leukoerythroblastosis, pancytopenia and leukopenia, while disseminated intravascular coagulation was detected in 11% of cases. In 23.6% of cases, BMM was amelanotic. The prognosis for BMM is grim, with a median survival of only 2 months. Conventional therapies for BMM remain largely ineffective, emphasizing the importance of considering bone marrow as a potential metastatic site in melanoma patients.

Published
2024

6. Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes.

Author

Knobler, R., Geroldinger‐Simić, M., Kreuter, A., Hunzelmann, N., Moinzadeh, P., Rongioletti, F., Denton, C. P., Mouthon, L., Cutolo, M., Smith, V., Gabrielli, A., Bagot, M., Olesen, A. B., Foeldvari, I., Jalili, A., Kähäri, V., Kárpáti, S., Kofoed, K., Olszewska, M., and Panelius, J.

Subjects
SYSTEMIC scleroderma, THERAPEUTICS, SKIN diseases, DIAGNOSIS, SCLERODERMA (Disease), SYNDROMES
Abstract

The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, updated strategies for the first‐ and advanced‐line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this consensus provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Gender differences in adult atopic dermatitis and clinical implication: Results from a nationwide multicentre study.

Author

Marani, A., Bianchelli, T., Gesuita, R., Faragalli, A., Foti, C., Malara, G., Micali, G., Amerio, P., Rongioletti, F., Corazza, M., Patrizi, A., Peris, K., Pimpinelli, N., Parodi, A., Fargnoli, M. C., Cannavo, S. P., Pigatto, P., Pellacani, G., Ferrucci, S. M., and Argenziano, G.

Subjects
ATOPIC dermatitis, ITCHING, AGE differences, WAIST-hip ratio, DISEASE duration, ADULTS
Abstract

Background: Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults. However, limited research has been conducted on gender differences in AD. Objectives: This study aimed to assess gender differences in adult AD patients, focusing on demographic and clinical features, comorbidities and treatment approaches. Methods: In this multicentre, observational, cross‐sectional study, we enrolled 686 adult patients with AD (357 males and 329 females). For each patient, we collected demographic data (age and sex), anthropometric measurements (weight, height, hip circumference, waist circumference and waist‐to‐hip ratio), clinical information (onset age, disease duration, severity, itching intensity, impact on quality of life) and noted comorbidities (metabolic, atopic and other). We recorded past and current topical and systemic treatments. We analysed all collected data using statistical techniques appropriate for both quantitative and qualitative variables. Multiple correspondence analysis (MCA) was employed to evaluate the relationships among all clinical characteristics of the patients. Results: We found no differences in age at onset, disease duration, severity and quality of life impact between males and females. Males exhibited higher rates of hypertriglyceridaemia and hypertension. No significant gender differences were observed in atopic or other comorbidities. Treatment approaches were overlapping, except for greater methotrexate use in males. MCA revealed distinct patterns based on gender, disease severity, age of onset, treatment and quality of life. Adult males with AD had severe disease, extensive treatments and poorer quality of life, while adult females had milder disease, fewer treatments and moderate quality of life impact. Conclusions: Our study reveals that gender differences in adult AD patients are largely due to inherent population variations rather than disease‐related disparities. However, it highlights potential undertreatment of females with moderate AD and quality of life impact, emphasizing the need for equitable AD treatment. JAK inhibitors may offer a solution for gender‐based therapeutic parity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Author

Chiricozzi, A, Di Nardo, L, Talamonti, M, Galluzzo, M, De Simone, C, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Antonelli, F, Ferrucci, S, Guarneri, F, Peris, K, Chiricozzi, A., Di Nardo, L., Talamonti, M., Galluzzo, M., De Simone, C., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., Savoia, P., Rubegni, P., Foti, C., Milanesi, N., Belloni Fortina, A., Bongiorno, M. R., Grieco, T., Di Nuzzo, S., Fargnoli, M. C., Carugno, A., Motolese, A., Rongioletti, F., Amerio, P., Balestri, R., Potenza, C., Micali, G., Patruno, C., Zalaudek, I., Lombardo, M., Feliciani, C., Antonelli, F., Ferrucci, S. M., Guarneri, F., Peris, K., Chiricozzi, A, Di Nardo, L, Talamonti, M, Galluzzo, M, De Simone, C, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Antonelli, F, Ferrucci, S, Guarneri, F, Peris, K, Chiricozzi, A., Di Nardo, L., Talamonti, M., Galluzzo, M., De Simone, C., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., Savoia, P., Rubegni, P., Foti, C., Milanesi, N., Belloni Fortina, A., Bongiorno, M. R., Grieco, T., Di Nuzzo, S., Fargnoli, M. C., Carugno, A., Motolese, A., Rongioletti, F., Amerio, P., Balestri, R., Potenza, C., Micali, G., Patruno, C., Zalaudek, I., Lombardo, M., Feliciani, C., Antonelli, F., Ferrucci, S. M., Guarneri, F., and Peris, K.

Published
2022

9. 'Your Skin Tells You' Campaign for Keratinocyte Cancers: When Individuals' Selection Makes the Difference

Author

Fargnoli, Maria Concetta, Antonetti, P., Atzori, L., Taddeucci, P., Di Stefani, Alessandro, Grandi, Vera, Lospalluti, L., Lacarrubba, F., Vaccari, Stefano, Amerio, P., Fabbrocini, G., Rossi, M., Campione, E., Caposiena Caro, R. D., Moscarella, E., Rongioletti, F., Pellegrini, C., Peris, Ketty, Discab, Fargnoli M. C., Di Stefani A., Grandi V., Vaccari S. (ORCID:0000-0001-9280-7626), Peris K. (ORCID:0000-0002-5237-0463), Fargnoli, Maria Concetta, Antonetti, P., Atzori, L., Taddeucci, P., Di Stefani, Alessandro, Grandi, Vera, Lospalluti, L., Lacarrubba, F., Vaccari, Stefano, Amerio, P., Fabbrocini, G., Rossi, M., Campione, E., Caposiena Caro, R. D., Moscarella, E., Rongioletti, F., Pellegrini, C., Peris, Ketty, Discab, Fargnoli M. C., Di Stefani A., Grandi V., Vaccari S. (ORCID:0000-0001-9280-7626), and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

Background: Prevention campaigns for skin cancers have focused primarily on melanoma, and over time there has been increasing awareness of the need to select the population to be screened to maximize program effectiveness. Objectives: The objective of the study was to report the results of a free dermatological initiative, as part of an awareness campaign dedicated to keratinocyte cancers, targeting individuals pre-selected through a short questionnaire. Methods: One day of dermatological consultations was held at 15 dermato-oncology referral centers during May 22-June 30, 2021. For selection, individuals answered a telephone interview consisting of 7 yes/no questions on risk factors. Demographics, clinical characteristics of suspicious tumors, and histopathologic diagnosis of excised lesions were collected. Suspicion rate, detection rate, and positive predictive values (PPVs) for any skin cancer, basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and melanoma were calculated. Results: A total of 320 individuals (56.9% males; 43.1% females) with a median age of 69.6 (range 21-91) years qualified for the screening initiative. Overall, skin cancers and precancerous lesions were diagnosed in 65.9% of the patients. Suspicion rate was 28.7% for any skin cancer (92/320), 22.8% for BCC (73/320), 4.7% for cSCC (15/320), and 1.2% for melanoma (4/320). Detection rate was 23.4% for any skin cancer (PPV 93.7%), 18.1% for BCC (PPV 95.1%), 4.4% for cSCC (PPV 93.3%), and 0.9% for melanoma (PPV 75%). Conclusions: Selection of individuals at high risk is a cost-effective approach for early detection campaigns for keratinocyte cancers.

Published
2023

10. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

Author

Chiricozzi, A, Talamonti, M, De Simone, C, Galluzzo, M, Gori, N, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Di Nardo, L, Guarneri, F, Peris, K, Caldarola, G, Silvaggio, D, Dattola, A, Napolitano, M, Ferrucci, S, Dal Bello, G, Bianchelli, T, Rovati, C, Pigliacelli, F, Ortoncelli, M, Hansel, K, Calabrese, G, Loi, C, Iannone, M, Veronese, F, Romita, P, Tronconi, G, Caroppo, F, Tilotta, G, Sernicola, A, Esposito, M, Raponi, F, Gualdi, G, Rech, G, Musumeci, M, Nistico, S, Campitiello, A, Bonzano, L, Piras, V, Chiricozzi A., Talamonti M., De Simone C., Galluzzo M., Gori N., Fabbrocini G., Marzano A. V., Girolomoni G., Offidani A., Rossi M. T., Bianchi L., Cristaudo A., Fierro M. T., Stingeni L., Pellacani G., Argenziano G., Patrizi A., Pigatto P., Romanelli M., Savoia P., Rubegni P., Foti C., Milanesi N., Belloni Fortina A., Bongiorno M. R., Grieco T., Di Nuzzo S., Fargnoli M. C., Carugno A., Motolese A., Rongioletti F., Amerio P., Balestri R., Potenza C., Micali G., Patruno C., Zalaudek I., Lombardo M., Feliciani C., Di Nardo L., Guarneri F., Peris K., Caldarola G., Silvaggio D., Dattola A., Napolitano M., Ferrucci S. M., Dal Bello G., Bianchelli T., Rovati C., Pigliacelli F., Ortoncelli M., Hansel K., Calabrese G., Loi C., Iannone M., Veronese F., Romita P., Tronconi G., Caroppo F., Tilotta G., Sernicola A., Esposito M., Raponi F., Gualdi G., Rech G., Musumeci M. L., Nistico S. P., Campitiello A., Bonzano L., Piras V., Chiricozzi, A, Talamonti, M, De Simone, C, Galluzzo, M, Gori, N, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Di Nardo, L, Guarneri, F, Peris, K, Caldarola, G, Silvaggio, D, Dattola, A, Napolitano, M, Ferrucci, S, Dal Bello, G, Bianchelli, T, Rovati, C, Pigliacelli, F, Ortoncelli, M, Hansel, K, Calabrese, G, Loi, C, Iannone, M, Veronese, F, Romita, P, Tronconi, G, Caroppo, F, Tilotta, G, Sernicola, A, Esposito, M, Raponi, F, Gualdi, G, Rech, G, Musumeci, M, Nistico, S, Campitiello, A, Bonzano, L, Piras, V, Chiricozzi A., Talamonti M., De Simone C., Galluzzo M., Gori N., Fabbrocini G., Marzano A. V., Girolomoni G., Offidani A., Rossi M. T., Bianchi L., Cristaudo A., Fierro M. T., Stingeni L., Pellacani G., Argenziano G., Patrizi A., Pigatto P., Romanelli M., Savoia P., Rubegni P., Foti C., Milanesi N., Belloni Fortina A., Bongiorno M. R., Grieco T., Di Nuzzo S., Fargnoli M. C., Carugno A., Motolese A., Rongioletti F., Amerio P., Balestri R., Potenza C., Micali G., Patruno C., Zalaudek I., Lombardo M., Feliciani C., Di Nardo L., Guarneri F., Peris K., Caldarola G., Silvaggio D., Dattola A., Napolitano M., Ferrucci S. M., Dal Bello G., Bianchelli T., Rovati C., Pigliacelli F., Ortoncelli M., Hansel K., Calabrese G., Loi C., Iannone M., Veronese F., Romita P., Tronconi G., Caroppo F., Tilotta G., Sernicola A., Esposito M., Raponi F., Gualdi G., Rech G., Musumeci M. L., Nistico S. P., Campitiello A., Bonzano L., and Piras V.

Abstract

Background: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. Methods: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. Conclusions: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.

Published
2021

11. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study

Author

Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nisticò, S. P., Giustini, S., Carugno, A., Cannavo’, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, K., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nisticò, S. P., Giustini, S., Carugno, A., Cannavo’, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., and Peris, K.

Abstract

Background: The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods: Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. Results: A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort 26 patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. Conclusion: The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen ‘cytokine storm’ of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.

Published
2021

14. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Author

Fargnoli, M. C., Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, K., Costanzo, A., Malara, G., Pellacani, G., Romanelli, M., Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, I., Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, R., Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Hansel, K., Fargnoli, M. C., Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, K., Costanzo, A., Malara, G., Pellacani, G., Romanelli, M., Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, I., Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, R., Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Fargnoli, Mc, Esposito, M, Ferrucci, S, Girolomoni, G, Offidani, A, Patrizi, A, Peris, K, Costanzo, A, Malara, G, Pellacani, G, Romanelli, M, Amerio, P, Cristaudo, A, Flori, Ml, Motolese, A, Betto, P, Patruno, C, Pigatto, P, Sirna, R, Stinco, G, Zalaudek, I, Bianchi, L, Boccaletti, V, Cannavò, Sp, Cusano, F, Lembo, S, Mozzillo, R, Gallo, R, Potenza, C, Rongioletti, F, Tiberio, R, Grieco, T, Micali, G, Persechino, S, Pettinato, M, Pucci, S, Savi, E, Stingeni, L, Romano, A, Argenziano, G, and Dupilumab Italian National Access Program (Dup-INAP, group).

Subjects
Male, Dermatitis, Severity of Illness Index, Cohort Studies, 030207 dermatology & venereal diseases, 0302 clinical medicine, Quality of life, Monoclonal, 80 and over, Humanized, Aged, 80 and over, Real-life, Atopic dermatitis, Middle Aged, Atopic dermatiti, Dupilumab, humanities, Treatment Outcome, atopic dermatitis, dupilumab, real-life, Female, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Cohort study, atopic dermatiti, Adult, medicine.medical_specialty, Context (language use), Dermatology, Antibodies, Monoclonal, Humanized, Antibodies, Atopic, Dermatitis, Atopic, 03 medical and health sciences, Young Adult, Internal medicine, Severity of illness, medicine, Humans, Adverse effect, Aged, Retrospective Studies, 030203 arthritis & rheumatology, business.industry, Pruritus, Retrospective cohort study, medicine.disease, Quality of Life, business, Sleep
Abstract

Background: Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Objective: To assess dupilumab effectiveness and safety in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort. Methods: Adult moderate-to-severe AD patients, referring to 39 Italian centers, received dupilumab in the context of a national patient access program. Disease assessment was performed at baseline, after 4 and 16 weeks of treatment using Eczema-Area-and-Severity-Index (EASI) score, itch and sleep numerical-rating-score (itch-NRS, sleep-NRS) and Dermatology-Life-Quality-Index (DLQI). Results: A total of 109 (71 M/38F) patients was studied. There was a significant reduction in EASI score, itch-NRS, sleep-NRS and DLQI from baseline to week 4 and a further significant decline to week 16. EASI 50, EASI75 and EASI90 were achieved by 59.6%, 28.4% and 9.3% of patients at 4 weeks and by 87.2%, 60.6% and 32.4% of them at 16 weeks, respectively. Adverse events were experienced by 19.2% (21/109) of the patients and they were all mild in intensity, being conjunctivitis the most common side effect. Conclusions: Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile.

Published
2021

15. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

Author

Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Belloni Fortina, A, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Venturini, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nistico, S, Giustini, S, Carugno, A, Cannavo, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Balestri, R, Bernardini, N, Botti, E, Burlando, M, Caldarola, G, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, M, Fidanza, R, Foti, C, Gambini, D, Gambardella, A, Girolomoni, G, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, M, Patrizi, A, Pellacani, G, Piaserico, S, Richetta, A, Rosi, E, Rossi, M, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Vezzoni, R, Zangrilli, A, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A. V., Potenza C., Conti A., Parodi A., Belloni Fortina A., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Venturini M., Bongiorno M. R., Feliciani C., Rubegni P., Amerio P., Fargnoli M. C., Pigatto P., Savoia P., Nistico S. P., Giustini S., Carugno A., Cannavo S. P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., Peris K., Balestri R., Bernardini N., Botti E., Burlando M., Caldarola G., Cattaneo A., Dapavo P., Dastoli S., De Simone C., Di Nuzzo S., Diotallevi F., Fierro M. T., Fidanza R., Foti C., Gambini D. M., Gambardella A., Girolomoni G., Guarneri C., Gualdi G., Hansel K., Megna M., Mugheddu C., Musumeci M. L., Patrizi A., Pellacani G., Piaserico S., Richetta A. G., Rosi E., Rossi M. T., Sacchelli L., Tiberio R., Tilotta G., Trovato E., Vezzoni R., Zangrilli A., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Belloni Fortina, A, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Venturini, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nistico, S, Giustini, S, Carugno, A, Cannavo, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Balestri, R, Bernardini, N, Botti, E, Burlando, M, Caldarola, G, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, M, Fidanza, R, Foti, C, Gambini, D, Gambardella, A, Girolomoni, G, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, M, Patrizi, A, Pellacani, G, Piaserico, S, Richetta, A, Rosi, E, Rossi, M, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Vezzoni, R, Zangrilli, A, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A. V., Potenza C., Conti A., Parodi A., Belloni Fortina A., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Venturini M., Bongiorno M. R., Feliciani C., Rubegni P., Amerio P., Fargnoli M. C., Pigatto P., Savoia P., Nistico S. P., Giustini S., Carugno A., Cannavo S. P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., Peris K., Balestri R., Bernardini N., Botti E., Burlando M., Caldarola G., Cattaneo A., Dapavo P., Dastoli S., De Simone C., Di Nuzzo S., Diotallevi F., Fierro M. T., Fidanza R., Foti C., Gambini D. M., Gambardella A., Girolomoni G., Guarneri C., Gualdi G., Hansel K., Megna M., Mugheddu C., Musumeci M. L., Patrizi A., Pellacani G., Piaserico S., Richetta A. G., Rosi E., Rossi M. T., Sacchelli L., Tiberio R., Tilotta G., Trovato E., Vezzoni R., and Zangrilli A.

Published
2020

16. Acute generalized exanthematous pustulosis with erythema multiforme-like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID-19)

Author

Robustelli Test, E, Vezzoli, P, Carugno, A, Raponi, F, Gianatti, A, Rongioletti, F, Sena, P, Robustelli Test, E., Vezzoli, P., Carugno, A., Raponi, F., Gianatti, A., Rongioletti, F., Sena, P., Robustelli Test, E, Vezzoli, P, Carugno, A, Raponi, F, Gianatti, A, Rongioletti, F, Sena, P, Robustelli Test, E., Vezzoli, P., Carugno, A., Raponi, F., Gianatti, A., Rongioletti, F., and Sena, P.

Published
2020

17. Dupilumab in atopic dermatitis: predictors of treatment outcome and time to response

Author

Nettis, E., Ferrucci, S. M., Pellacani, G., Di Leo, E., Argenziano, G., Foti, C., Rongioletti, F., Patruno, C., Ortoncelli, M., Macchia, L., Tavecchio, S., Bonzano, L., Di Bona, D., Calabrese, G., Fabbrocini, G., Romita, P, Piras, V, Bennardo, L, Ribero, S, Napolitano, M, Bilancia, M, Detoraki, A, Nettis, E., Ferrucci, S. M., Pellacani, G., Di Leo, E., Argenziano, G., Foti, C., Rongioletti, F., Patruno, C., Ortoncelli, M., Macchia, L., Tavecchio, S., Bonzano, L., Di Bona, D., Calabrese, G., Fabbrocini, G., Romita, P, Piras, V, Bennardo, L, Ribero, S, Napolitano, M, Bilancia, M, and Detoraki, A

Subjects
medicine.medical_specialty, business.industry, Treatment outcome, MEDLINE, Eczema, Patient characteristics, Dermatology, Atopic dermatitis, medicine.disease, Antibodies, Monoclonal, Humanized, Dupilumab, Severity of Illness Index, Dermatitis, Atopic, Infectious Diseases, Treatment Outcome, Medicine, Humans, business, Human
Abstract

Recently, dupilumab, an anti-IL-4Rα antibody, has become available for the treatment of moderate-to-severe atopic dermatitis (AD).1-4 Baseline patient characteristics that can be used as predictors of response to dupilumab treatment in AD patients have not yet been identified.

Published
2021

18. Correction to: Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study (Archives of Dermatological Research, (2022), 314, 6, (593-603), 10.1007/s00403-021-02243-w)

Author

Campanati, A., Bianchelli, T., Gesuita, R., Foti, C., Malara, G., Micali, G., Amerio, P., Rongioletti, F., Corazza, M., Patrizi, A., Peris, Ketty, Pimpinelli, N., Parodi, A., Fargnoli, Maria Concetta, Cannavo, S. P., Pigatto, P., Pellacani, G., Ferrucci, S. M., Argenziano, G., Cusano, F., Fabbrocini, G., Stingeni, L., Potenza, M. C., Romanelli, Margherita, Bianchi, L., Offidani, A., Romita, P., Musumeci, M. L., Piras, V., Borghi, Anna Maria, Loi, C., Gori, Niccolo', Prigano, F., Gallo, Rosanna, Esposito, M., Campitello, A., Bolzano, L., Tavecchio, S., Calabrese, G., Di Costanzo, L., Hansel, K., Skroza, N., Tolino, E., Tonini, Gerolamo, Talamonti, M., Peris K. (ORCID:0000-0002-5237-0463), Fargnoli M. C., Romanelli M., Borghi A., Gori N., Gallo R., Tonini G., Campanati, A., Bianchelli, T., Gesuita, R., Foti, C., Malara, G., Micali, G., Amerio, P., Rongioletti, F., Corazza, M., Patrizi, A., Peris, Ketty, Pimpinelli, N., Parodi, A., Fargnoli, Maria Concetta, Cannavo, S. P., Pigatto, P., Pellacani, G., Ferrucci, S. M., Argenziano, G., Cusano, F., Fabbrocini, G., Stingeni, L., Potenza, M. C., Romanelli, Margherita, Bianchi, L., Offidani, A., Romita, P., Musumeci, M. L., Piras, V., Borghi, Anna Maria, Loi, C., Gori, Niccolo', Prigano, F., Gallo, Rosanna, Esposito, M., Campitello, A., Bolzano, L., Tavecchio, S., Calabrese, G., Di Costanzo, L., Hansel, K., Skroza, N., Tolino, E., Tonini, Gerolamo, Talamonti, M., Peris K. (ORCID:0000-0002-5237-0463), Fargnoli M. C., Romanelli M., Borghi A., Gori N., Gallo R., and Tonini G.

Abstract

In this article the author group details were incorrectly displayed with Collaborators included in the main author group. M. Talamonti (Dermatology Unit, Policlinico Tor Vergata Rome, University of Rome Tor Vergata, Rome, Italy). The original article has been corrected.

Published
2022

19. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb Study

Author

Pellacani, G., Bigi, L., Parodi, A., Burlando, M., Lanna, C., Campione, E., Rongioletti, F., Mugheddu, C., Malara, G., Moretti, G., Stingeni, L., Hansel, K., Micali, G., Naldi, L., Pirro, Federico, Peris, Ketty, Pirro F., Peris K. (ORCID:0000-0002-5237-0463), Pellacani, G., Bigi, L., Parodi, A., Burlando, M., Lanna, C., Campione, E., Rongioletti, F., Mugheddu, C., Malara, G., Moretti, G., Stingeni, L., Hansel, K., Micali, G., Naldi, L., Pirro, Federico, Peris, Ketty, Pirro F., and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

This open-label multicentre trial evaluated the efficacy and safety of oral dimethyl fumarate (DMF) in patients with moderate-to-severe plaque psoriasis in real-life clinical practice over 52 weeks. Disease severity and improvement were assessed using the psoriasis area severity index (PASI), body surface area (BSA) affected, and Physician Global Assessment (PGA). Quality of life (QoL) was assessed using the Dermatology Life Quality Index (DLQI) questionnaire. The visual analogue scale (VAS) was used to quantify pruritus and measure treatment satisfaction. A total of 141 patients were included, being 66.7% male, aged 49.1 ± 14.7 years and with disease duration of 16 ± 12.1 years. After 52 weeks, mean PASI decreased from 15.9 ± 6.8 to 1.5 ± 2 and 87.7%, 56.9% and 24.6% of patients achieved PASI 75/90/100 response, respectively. BSA decreased from 26.5 ± 14.8% to 2.7 ± 3.5% at 52 weeks, and 81.5% of patients had a PGA 0-1. DLQI scores decreased from 9.4 ± 6.4 to 2.1 ± 3.3, and VAS of pruritus decreased from 53 ± 28.4 to 19.1 ± 26.2 at Week 52. VAS for treatment satisfaction was 79.4 ± 29.4 at Week 52. A total of 34.2% of patients had an AE leading to permanent discontinuation. These findings show that DMF can significantly improve indices of disease severity, pruritus and QoL, with high levels of patient satisfaction and similar safety profile to other fumarates.

Published
2022

20. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis

Author

Gisondi, P., Fargnoli, M. C., Amerio, P., Argenziano, G., Bardazzi, F., Bianchi, L., Chiricozzi, Andrea, Conti, A., Corazza, M., Costanzo, A., Dapavo, P., De Simone, Clara, Fabbrocini, G., Feliciani, C., Foti, C., Girolomoni, G., Guarneri, C., Marzano, A. V., Micali, G., Offidani, A., Parodi, A., Pellacani, G., Piaserico, S., Prignano, F., Romanelli, M., Rongioletti, F., Rubegni, P., Stinco, G., Stingeni, L., Tomasini, C. F., Venturini, M., Peris, Ketty, Calzavara-Pinton, P., Chiricozzi A. (ORCID:0000-0002-6739-0387), DE Simone C. (ORCID:0000-0002-0898-0045), Peris K. (ORCID:0000-0002-5237-0463), Gisondi, P., Fargnoli, M. C., Amerio, P., Argenziano, G., Bardazzi, F., Bianchi, L., Chiricozzi, Andrea, Conti, A., Corazza, M., Costanzo, A., Dapavo, P., De Simone, Clara, Fabbrocini, G., Feliciani, C., Foti, C., Girolomoni, G., Guarneri, C., Marzano, A. V., Micali, G., Offidani, A., Parodi, A., Pellacani, G., Piaserico, S., Prignano, F., Romanelli, M., Rongioletti, F., Rubegni, P., Stinco, G., Stingeni, L., Tomasini, C. F., Venturini, M., Peris, Ketty, Calzavara-Pinton, P., Chiricozzi A. (ORCID:0000-0002-6739-0387), DE Simone C. (ORCID:0000-0002-0898-0045), and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permission of EuroGuiDerm, SIDeMaST adapted the guideline to the Italian healthcare context to supply a reliable and affordable tool to Italian physicians who take care of patients affected by moderate to severe plaque psoriasis. The content of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline, suggestions for disease severity grading and treatment goals. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs including acitretin, cyclosporine, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab. Moreover, the guideline provides guidance for specific clinical situations such as patient with concomitant psoriatic arthritis, inflammatory bowel disease, a history of malignancies, a history of depression, diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or those with childbearing potential. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.

Published
2022

21. European dermatology forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis

Author

Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C.P., Rudnicka, L., Frasin, L.A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Braae Olesen, A., Foeldvari, I., Frances, C., Jalili, A., Just, U., Kähäri, V., Kárpáti, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J.M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkötter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N.J., and Krieg, T.

Published
2017
Full Text
View/download PDF

23. European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes

Author

Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C.P., Rudnicka, L., Frasin, L.A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Braae Olesen, A., Foeldvari, I., Frances, C., Jalili, A., Just, U., Kähäri, V., Kárpáti, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J.M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkötter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N.J., and Krieg, T.

Published
2017
Full Text
View/download PDF

29. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study

Author

Nettis, E, primary, Ferrucci, SM, additional, Ortoncelli, M, additional, Pellacani, G, additional, Foti, C, additional, Di Leo, E, additional, Patruno, C, additional, Rongioletti, F, additional, Argenziano, G, additional, Macchia, L, additional, Tavecchio, S, additional, Napolitano, M, additional, Ribero, S, additional, Bonzano, L, additional, Romita, P, additional, Di Bona, D, additional, Nisticò, SP, additional, Piras, V, additional, Calabrese, G, additional, Detoraki, C, additional, Carbonara, M, additional, and Fabbrocini, G, additional

Published
2022
Full Text
View/download PDF

31. SarS-CoV-2 vaccines and biological treatments: Dermatological perspectives

Author

Stingeni L., Bianchi L., Peris K., Fabbrocini G., Micali G., Calzavara-Pinton P., Tramontana M., Hansel K., Rongioletti F., on behalf of SIDemaSt, Stingeni, L., Bianchi, L., Peris, K., Fabbrocini, G., Micali, G., Calzavara-Pinton, P., Tramontana, M., Hansel, K., Stingeni L., Bianchi L., Peris K., Fabbrocini G., Micali G., Calzavara-Pinton P., Tramontana M., Hansel K., Piraccini B.M., Rongioletti, F., and on behalf of, Sidemast

Subjects
2019-20 coronavirus outbreak, Settore MED/35 - Malattie Cutanee e Veneree, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Skin Disease, fungi, COVID-19, Dermatology, Virology, Skin Diseases, body regions, Biological Therapy, Infectious Diseases, Medicine, Humans, biological treatment, business, skin and connective tissue diseases, Human
Abstract

More than 60 SARS-CoV-2 vaccine candidates are currently in clinical trials and more than 170 vaccines are in different stages of preclinical evaluation worldwide

Published
2021

32. Clinicopathologic features between different viral epidemic outbreaks involving the skin: Dermatologic involvement in viral outbreaks

Author

Atzori L., Ferreli C., Mateeva V., Vassileva S., Rongioletti F., Atzori, L., Ferreli, C., Mateeva, V., Vassileva, S., and Rongioletti, F.

Subjects
SARS-CoV-2, Humans, COVID-19, Pandemics, Disease Outbreaks, Skin
Abstract

The current coronavirus disease 2019 pandemic has exceeded any epidemiologic prevision, but increasing information suggests some analogies with the major viral outbreaks of the last century. A general warning has been issued on the possibility that coinfections can make differential diagnosis and treatment difficult, especially in tropical countries. Some reports have pointed out that the presence of high Dengue antibodies can give a false-negative result for severe acute respiratory syndrome coronavirus 2. Mucocutaneous manifestations are very frequent, with an apparent overlap among different pathogens. A strong clinicopathologic correlation, however, may provide some clues to address the differential. Waiting for laboratory and instrumental results, the timing and distribution of skin lesions is often pathognomonic. Histopathologic findings characterize certain reaction patterns and provide insights on pathogenetic mechanisms. Unfortunately, skin assessments, especially invasive exams such as biopsy, are less important in severely ill patients. A literature review was performed to collect information from other epidemics to counteract what has become the most frightening disease of our time.

Published
2021

33. Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study

Author

Patruno, C., Fabbrocini, G., Longo, G., Argenziano, G., Ferrucci, S. M., Stingeni, L., Peris, K., Ortoncelli, M., Offidani, A., Amoruso, G. F., Talamonti, M., Girolomoni, G., Grieco, T., Iannone, M., Nettis, E., Foti, C., Rongioletti, F., Corazza, M., Veneri, M. D., Napolitano, M., Angileri, L., Bianchelli, T., Borghi, A., Calabrese, G., Chello, C., Dal Bello, G., Dastoli, S., Ferrillo, M., Galluzzo, M., Gori, N., Hansel, K., Macchia, L., Piras, V., Provenzano, E., Ribero, S., Romanelli, M., Romita, P., Patruno, C., Fabbrocini, G., Longo, G., Argenziano, G., Ferrucci, S. M., Stingeni, L., Peris, K., Ortoncelli, M., Offidani, A., Amoruso, G. F., Talamonti, M., Girolomoni, G., Grieco, T., Iannone, M., Nettis, E., Foti, C., Rongioletti, F., Corazza, M., Veneri, M. D., Napolitano, M., Angileri, L., Bianchelli, T., Borghi, A., Calabrese, G., Chello, C., Dal Bello, G., Dastoli, S., Ferrillo, M., Galluzzo, M., Gori, N., Hansel, K., Macchia, L., Piras, V., Provenzano, E., Ribero, S., Romanelli, M., and Romita, P.

Subjects
Male, medicine.medical_specialty, Time Factors, Injections, Subcutaneous, Socio-culturale, Dermatology, Antibodies, Monoclonal, Humanized, Eczema Area and Severity Index, elderly, Severity of Illness Index, Drug Administration Schedule, Dermatitis, Atopic, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, Settore MED/35, Internal medicine, atopic dermatitis, dupilumab, medicine, Humans, Adverse effect, Contraindication, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Pruritus, Age Factors, General Medicine, Atopic dermatitis, Dermatology Life Quality Index, medicine.disease, Conjunctivitis, Dupilumab, Injection Site Reaction, Treatment Outcome, Quality of Life, Observational study, Female, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business
Abstract

Objective: The objective of this study was to assess the effectiveness and safety of dupilumab in treating elderly patients with atopic dermatitis from baseline to 52 weeks. Methods: A retrospective observational real-life study was conducted in a group of elderly patients with severe atopic dermatitis treated with dupilumab for 52 weeks. Inclusion criteria were: age ≥ 65 years; diagnosis of atopic dermatitis made by an expert dermatologist; Eczema Area and Severity Index ≥ 24; and a contraindication, side effects, or failure to respond to cyclosporine. The primary outcome was the mean percentage reduction in the Eczema Area and Severity Index score from baseline to week 52. Secondary measures includedthe mean percentage reduction in the Pruritus and Sleep Numerical Rating Scales and the Dermatology Life Quality Index, and the types and rates of adverse events from baseline to week 52. Results: One hundred and five patients were eligible for the study. Flexural dermatitis was the most frequent clinical phenotype (63.8%). The coexistence of more than one clinical phenotype was found in 70/105 (66.6%) patients. We observed a reduction in all disease severity scores from baseline to week 52 (p < 0.001). Adverse events were recorded in 30/105 (28.6%) patients, with conjunctivitis and injection-site reaction the most frequent. Conclusions: In this study, dupilumab is an effective and safe treatment for the long-term management of atopic dermatitis in patients aged over 65 years.

Published
2021

34. Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists and Public Health (ADOI), the Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), the Italian Society of Pediatric Allergy and Immunology (SIAIP), the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA), and the Italian Society of Pediatric Dermatology (SIDerP)

Author

Calzavara-Pinton P., Fortina A. B., Bonamonte D., Marseglia G. L., Del Giudice M. M., Musarra A., Nettis E., Neri I., Patruno C., Stingeni L., Peris K., Rongioletti F., on behalf of raDar group, Calzavara-Pinton, P., Fortina, A. B., Bonamonte, D., Marseglia, G. L., Del Giudice, M. M., Musarra, A., Nettis, E., Neri, I., Patruno, C., Stingeni, L., Peris, K., Rongioletti, F., and on behalf of raDar, Group

Subjects
Adult, therapy, Consensus, Adolescent, Dermatitis, Dermatology, Dupilumab, Atopic, Hospitals, Asthma, Dermatitis, Atopic, Infectious Diseases, Allergists, Italy, Venereology, Diagnosis, Quality of Life, Humans, Therapy, Public Health, Child, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Dermatologists, Atopic dermatitis
Abstract

Atopic dermatitis (AD) is a chronic inflammatory disease with increasing global incidence, which has a multifactorial pathogenesis and a variable expressivity. Clinical features of AD are different in adults compared to children, but it is well recognized the substantial impact of the disease on patients' quality of life at any age. Indeed, little is known about AD in adolescence, a period of life generally associated with high psychological burden and vulnerability to depression. Guidelines for the management of AD are available for both children and adults but specific guidelines for the diagnosis and treatment of AD in adolescents are lacking. Seven Italian scientific societies of dermatologists, allergists, and pediatric allergists joined in a specific meeting to provide practical guidance for the diagnosis and management of moderate-to-severe adolescent AD suitable for the Italian clinical practice. Through a modified Delphi procedure, consensus was reached by 59 Italian experts in the management of AD on 20 statements covering five areas of interest about adolescent AD, including disease complexity, burden and social impact, diagnosis and defini tion of severity, current treatments, and new biologic therapies. This paper reports recommendations for the diagnosis and management of AD specifically in adolescents, pointing out some peculiar clinical features and focusing on the choice of medications. Dupilumab, the first biologic approved for the treatment of adolescents with AD, represents a useful treatment option due to its efficacy and reassuring safety profile.

Published
2021

35. Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis. The LION real-life multicenter prospective observational cohort study

Author

Campanati, A., Atzori, L., Potenza, C., Damiani, G., Bianchi, L., Corazza, M., Tiberio, R., Prignano, F., Argenziano, G., Fargnoli, M. C., Stingeni, L., Mazzotta, A., De Pita, O., Mazzatenta, C., Feliciani, C., Donini, M., Offidani, A., Peris, K., Rongioletti, F., Pigatto, P., Cruciani, G., De Simone, C., Caldarola, G., Grimaldi, M., Anedda, J., Bernardini, N., Marchesiello, A., Franchi, C., Dattola, A., Botti, E., Zedde, P., Cammarata, E., Radi, G., Rosi, E., De Rosa, A., Esposito, M., Marietti, R., Lupi, F., Grazzini, M., Domenico, D. M., Brusasco, M., Gai, F., Campanati, A., Atzori, L., Potenza, C., Damiani, G., Bianchi, L., Corazza, M., Tiberio, R., Prignano, F., Argenziano, G., Fargnoli, M. C., Stingeni, L., Mazzotta, A., De Pita, O., Mazzatenta, C., Feliciani, C., Donini, M., Offidani, A., Peris, K., Rongioletti, F., and on behalf of the LION study group—Italian Participating, Centers

Subjects
Adult, Male, medicine.medical_specialty, Dermatologic Agent, psoriasis, therapy-topical, Betamethasone dipropionate, Dermatology, Betamethasone, NO, chemistry.chemical_compound, Patient satisfaction, Calcitriol, Psoriasis, Internal medicine, Drug Combination, medicine, Humans, Prospective Studies, Prospective cohort study, Calcipotriol, psoriasi, therapy-topical, business.industry, psoriasis, General Medicine, Middle Aged, medicine.disease, Prospective Studie, Drug Combinations, Treatment Outcome, chemistry, Patient Satisfaction, Cohort, Observational study, Dermatologic Agents, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business, Cohort study, medicine.drug, Human
Abstract

Topical treatment is the mainstay for mild or moderate psoriasis, but patients are generally little satisfied. Calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam has shown to improve signs and symptoms in plaque psoriasis patients. This study assessed patient's satisfaction with Cal/BD foam in a real-life Italian dermatological clinical practice. A multicenter, 4-week observational prospective cohort study enrolled, in 17 Italian dermatology clinics, adult patients with plaque psoriasis on the body and/or scalp. Treatment satisfaction was assessed by 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9), preference over previous treatments by Patient Preference Questionnaire (PPQ), and change in disease state by Psoriasis Area Severity Index (PASI). Overall 256 patients were eligible, with a mean (SD) age of 55.6 (15.4) years, 59.4% were males. Psoriasis severity was mild in 52.0% of patients, moderate in 43.3%, and severe in 4.7%. Scalp involvement was present in 36.7% of patients. Previous antipsoriatic treatments had been received by 80.5% of patients. TSQM-9 median (25th-75th percentile) scores were 83.3 (66.7-88.9) for effectiveness, 77.8 (66.7-88.9) for convenience, and 78.6 (64.3-92.9) for global satisfaction. Mean (SD) PASI value decreased from 7.3 (4.8) to 2.1 (2.7) after 4 weeks. More than 90% of patients previously treated for psoriasis evaluated the Cal/BD foam more effective, easier to use and better tolerated compared to previous topical treatments at PPQ. This observational study provides real-life evidence of a high level of satisfaction with effectiveness and convenience of the Cal/BD foam in a cohort of plaque psoriasis patients, with an objective improvement in PASI.

Published
2021

36. Fatal hyalohyphomycosis with cutaneous involvement caused by purpureocillium lilacinum in an immunocompromised patient with bullous pemphigoid

Author

Corbeddu M., Ferreli C., Cappai R., Ferraguti P., Atzori L., Pilloni L., Rongioletti F., Corbeddu, M., Ferreli, C., Cappai, R., Ferraguti, P., Atzori, L., Pilloni, L., and Rongioletti, F.

Subjects
Male, Hyalohyphomycosis, Immunocompromised Host, Hypocreales, Pemphigoid, Bullous, Humans, Paecilomyces
Abstract

Emergent pathogen as Purpureocillium lilacinum are becoming cause of morbidity and mortality in our population, especially in immunocompromised patients. We describe a case of hyalohyphomycosis in a diabetic man under systemic steroid treatment for a bullous pemphigoid. Treatment with different antimycotic drugs were ineffective and infection spread diffusely, leading to deterioration of general conditions and ultimately death. The aim of this article is to increase awareness of clinicians about this uncommon, but frequently fatal refractory mycotic infection.

Published
2021

40. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study

Author

Patruno C., Napolitano M., Argenziano G., Peris K., Ortoncelli M., Girolomoni G., Offidani A., Ferrucci S. M., Amoruso G. F., Rossi M., Stingeni L., Malara G., Grieco T., Foti C., Gattoni M., Loi C., Iannone M., Talamonti M., Stinco G., Rongioletti F., Pigatto P. D., Cristaudo A., Nettis E., Corazza M., Guarneri F., Amerio P., Esposito M., Belloni Fortina A., Potenza C., Fabbrocini G., Angileri L., Bianchelli T., Borghi A., Buligan C., Calabrese G., Calzavara Pinton P., Caroppo F., Chello C., Dal Bello G., Damiani G., Fargnoli M. C., Ferrillo M., Galluzzo M., Gori N., Gualdi G., Hansel K., Macchia L., Mariano M., Nistico S. P., Pertusi G., Piras V., Provenzano E., Ravaioli G. M., Ribero S., Romanelli M., Romita P., Tolino E., Trifiro C., Patruno, C., Napolitano, M., Argenziano, G., Peris, K., Ortoncelli, M., Girolomoni, G., Offidani, A., Ferrucci, S. M., Amoruso, G. F., Rossi, M., Stingeni, L., Malara, G., Grieco, T., Foti, C., Gattoni, M., Loi, C., Iannone, M., Talamonti, M., Stinco, G., Rongioletti, F., Pigatto, P. D., Cristaudo, A., Nettis, E., Corazza, M., Guarneri, F., Amerio, P., Esposito, M., Belloni Fortina, A., Potenza, C., Fabbrocini, G., Angileri, L., Bianchelli, T., Borghi, A., Buligan, C., Calabrese, G., Calzavara Pinton, P., Caroppo, F., Chello, C., Dal Bello, G., Damiani, G., Fargnoli, M. C., Ferrillo, M., Galluzzo, M., Gori, N., Gualdi, G., Hansel, K., Macchia, L., Mariano, M., Nistico, S. P., Pertusi, G., Piras, V., Provenzano, E., Ravaioli, G. M., Ribero, S., Romanelli, M., Romita, P., Tolino, E., and Trifiro, C.

Subjects
Adult, medicine.medical_specialty, Adolescent, multicentre, Treatment outcome, Eczema, Socio-culturale, Dermatitis, Dupilumab, atopic dermatitis, multicentre, real-life study, Dermatology, Antibodies, Monoclonal, Humanized, elderly, Severity of Illness Index, Antibodies, Atopic, Dermatitis, Atopic, 030207 dermatology & venereal diseases, 03 medical and health sciences, Young Adult, Settore MED/35, 0302 clinical medicine, Internal medicine, Aged, Humans, Middle Aged, Retrospective Studies, Monoclonal, Medicine, 030212 general & internal medicine, Adverse effect, Humanized, atopic dermatitis, business.industry, dupilumab, Atopic dermatitis, medicine.disease, humanities, Safety profile, Infectious Diseases, Observational study, real-life study, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Life study, business, Prurigo nodularis
Abstract

Background: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. Objectives: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65years and affected by severe AD. Their main clinical features were also examined. Methods: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16weeks of treatment. Results: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18–64years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. Conclusions: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.

Published
2020

41. SARS‐CoV, Mers‐CoV and COVID‐19: what differences from a dermatological viewpoint?

Author

Rongioletti, F. and Rongioletti, F.

Subjects
2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Middle East respiratory syndrome coronavirus, viruses, Pneumonia, Viral, Severe disease, Dermatology, medicine.disease_cause, Letter to Editor, Skin Diseases, skin manifestations, Betacoronavirus, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, MERS, Pandemic, medicine, Humans, 030212 general & internal medicine, skin and connective tissue diseases, Pandemics, Coronavirus, SARS, Covid‐19, biology, SARS-CoV-2, business.industry, fungi, COVID-19, virus diseases, Outbreak, biology.organism_classification, Virology, respiratory tract diseases, Infectious Diseases, Severe acute respiratory syndrome-related coronavirus, Middle East Respiratory Syndrome Coronavirus, coronavirus outbreaks, Coronavirus Infections, business
Abstract

Over the past two decades, 3 zoonotic global coronavirus outbreaks have occurred: 1. SARS starting in 2002 in China due to SARS‐CoV; 2. MERS starting in 2012 in Saudi Arabia due to MERS‐CoV; 3. Covid‐19 due to SARS‐CoV‐2 starting in 2019 in Wuhan, China (1). Both beta‐coronaviruses, SARS‐CoV and MERS‐CoV caused a severe disease in most infected people.

Published
2020

42. Hidradenitis suppurativa epidemiology. From the first Italian registry in 2009 to the most recent epidemiology updates - Italian Registry Hidradenitis Suppurativa project 2

Author

Bettoli, V., Cazzaniga, S., Scuderi, V., Zedde, P., Di Landro, A., Naldi, L., Cannavò, S., Fabbrocini, G., Marzano, A. V., Mazzanti, C., Offidani, A., Patrizi, A., Pellacani, G., Pimpinelli, N., Potenza, C., Romanelli, M., Rongioletti, F., Bettoli, V., Cazzaniga, S., Scuderi, V., Zedde, P., Di Landro, A., Naldi, L., Cannavo, S., Fabbrocini, G., Marzano, A. V., Mazzanti, C., Offidani, A., Patrizi, A., Pellacani, G., Pimpinelli, N., Potenza, C., Romanelli, M., Rongioletti, F., Bettoli V., Cazzaniga S., Scuderi V., Zedde P., Di Landro A., Naldi L., Cannavo S., Fabbrocini G., Marzano A.V., Mazzanti C., Offidani A., Patrizi A., Pellacani G., Pimpinelli N., Potenza C., Romanelli M., and Rongioletti F.

Subjects
Adult, Male, Registrie, medicine.medical_specialty, MEDLINE, Dermatology, Body Mass Index, 030207 dermatology & venereal diseases, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Age Distribution, Epidemiology, medicine, Prevalence, Humans, Hidradenitis suppurativa, Registries, Young adult, Age of Onset, Sex Distribution, business.industry, Incidence (epidemiology), Incidence, Smoking, hidradenitis suppurativa, medicine.disease, Infectious Diseases, Italy, 030220 oncology & carcinogenesis, Age distribution, Female, Age of onset, business, Body mass index, Demography, Human
Abstract

BACKGROUND The incidence of hidradenitis suppurativa (HS) is still not fully established with only a few studies reporting its estimates. Prevalence estimates range from 5:10 000 to 4:100. These extremely large variations could be explained by a combination of factors, including different selection procedures, different diagnostic criteria, and variations in the sex and age distribution of the examined samples. OBJECTIVES To analyze variations between two consecutive Italian Registries on HS. METHODS Data obtained from the second Italian Registry on HS, named 'Italian Registry Hidradenitis Suppurativa (IRHIS) Project 2', are compared to the previous first Italian registry on HS. RESULTS Data on 944 patients are reported. The more relevant aspects that characterize IRHIS 2 project, in comparison with the previous first Italian Registry on HS, are as follows: (i) the total number of patients, about fourfold higher; (ii) a more uniform national geographic distribution of the patient population; (iii) a larger number of dermatology units involved; (iv) a larger number of items considered in the data collection; (v) 6 years of difference between the onset of the two registries (2009-2013 vs. 2015-2019). Comparing data of the two registries, there are no statistically significant differences in terms of age at the time of the visit, gender, BMI, smoking habits, age at onset and age at first diagnosis by physician. Interestingly, the mean Sartorius score in the IRHIS project 2 (58.8) was significantly lower compared to the first Italian Registry (78.4). CONCLUSIONS The importance of the registries, at both national and international levels, in collecting useful real-life data is confirmed by these two Italian projects.

Published
2019

43. Ultrasonography in the pathway to an optimal standard of care of hidradenitis suppurativa: the Italian Ultrasound Working Group experience

Author

Lacarrubba, F., Dini, V., Napolitano, M., Venturini, M., Caposiena Caro, D. R., Molinelli, E., Passoni, E., Monfrecola, G., Argenziano, G., Berti, E., Bianchi, L., Calzavara Pinton, P., Cannavo, S. P., Costanzo, A., Donini, M., Fabbrocini, G., Fierro, M. T., Micali, G., Offidani, A., Parodi, A., Patrizi, A., Pellacani, G., Peris, K., Pimpinelli, N., Potenza, C., Romanelli, M., Rongioletti, F., Solivetti, F., Lacarrubba, F., Dini, V., Napolitano, M., Venturini, M., Caposiena Caro, D. R., Molinelli, E., Passoni, E., Monfrecola, G., Argenziano, G., Berti, E., Bianchi, L., Calzavara Pinton, P., Cannavo, S. P., Costanzo, A., Donini, M., Fabbrocini, G., Fierro, M. T., Micali, G., Offidani, A., Parodi, A., Patrizi, A., Pellacani, G., Peris, K., Pimpinelli, N., Potenza, C., Romanelli, M., Rongioletti, F., Solivetti, F., Lacarrubba F., Dini V., Napolitano M., Venturini M., Caposiena Caro D.R., Molinelli E., Passoni E., Monfrecola G., Argenziano G., Berti E., Bianchi L., Calzavara Pinton P., Cannavo S.P., Costanzo A., Donini M., Fabbrocini G., Fierro M.T., Micali G., Offidani A., Parodi A., Patrizi A., Pellacani G., Peris K., Pimpinelli N., Potenza C., Romanelli M., Rongioletti F., and Solivetti F.

Subjects
Adult, Male, medicine.medical_specialty, Standard of care, Dermatology, Severity of Illness Index, 030207 dermatology & venereal diseases, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Disease severity, Retrospective Studie, Internal medicine, medicine, Humans, Hidradenitis suppurativa, Radiation treatment planning, Grading (tumors), Physical Examination, Retrospective Studies, Ultrasonography, Settore MED/35 - Malattie Cutanee e Veneree, business.industry, Ultrasound, Retrospective cohort study, Middle Aged, medicine.disease, Hidradenitis Suppurativa, Infectious Diseases, Ultrasound Working Group experience, 030220 oncology & carcinogenesis, Female, business, Human
Abstract

Background: Ultrasound (US) is a real-time non-invasive technique that has been demonstrated to support an early diagnosis and a more precise assessment of hidradenitis suppurativa (HS). Objectives: To compare the clinical and US evaluation of a series of HS patients. Methods: 434 HS patients (259 F, 175 M; mean age 33.82 ±13.31 years) observed across 19 Italian dermatology centres [members of the Italian Ultrasound Working Group (IUWG)] were enrolled in a retrospective study. Clinical staging was obtained by the Hidradenitis Suppurativa Physician's Global Assessment score (HS-PGA), while the ultrasonographic staging was determined by the US HS-PGA, based on the same scores as clinical HS-PGA but performed with the aid of US. Results: At the end of the study, the mean clinical and US HS-PGA scores were 2.70 and 2.92, respectively. Direct comparison of clinical and ultrasonographic assessment revealed that a higher proportion of patients was classified as having moderate and very severe disease by US. In particular, 117 patients (26.96%) had a worse classification by US HS-PGA compared to clinical assessment. Conclusion: Our findings confirm that the use of clinical grading only to assess HS severity may underestimate the real disease severity. US examination can be considered an essential non-invasive imaging tool available to dermatologists for a more accurate diagnosis, staging, treatment planning and monitoring of HS and should be included in the pathway to an optimal standard of care of HS.

Published
2019

44. The Italian dermatologic community facing COVID-19 pandemic: Recommendation from the Italian society of dermatology and venereology

Author

Micali, G., Musumeci, M. L., Peris, Ketty, Pinton, P. C., Conti, A., Fabbrocini, G., Frascione, P., Pigatto, P., Piraccini, B. M., Rongioletti, F., Rubegni, P., Stingeni, L., Micali G, Musumeci ML, Peris K, Piraccini B.M., Board Members of the SIDeMaST., Micali, G., Musumeci, M. L., Peris, K., Pinton, P. C., Conti, A., Fabbrocini, G., Frascione, P., Pigatto, P., Piraccini, B. M., Rongioletti, F., Rubegni, P., and Stingeni, L.

Subjects
medicine.medical_specialty, 2019-20 coronavirus outbreak, Venereology, Infectious Disease Transmission, Patient-to-Professional, Coronavirus disease 2019 (COVID-19), COVID, hospital, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Infectious Disease Transmission, Pneumonia, Viral, Viral transmission, Sexually Transmitted Diseases, Dermatology, Betacoronavirus, COVID-19, Coronavirus Infections, Humans, Infection Control, Italy, Pandemics, Practice Guidelines as Topic, SARS-CoV-2, Skin Diseases, Patient-to-Professional, Pandemic, medicine, Viral, Sexually Transmitted Disease, Betacoronaviru, Coronavirus Infection, business.industry, Infectious disease transmission, Skin Disease, Pneumonia, Family medicine, business, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Human
Abstract

The “Società Italiana di Dermatologia medica, chirurgica, estetica e delle Malattie Sessualmente Trasmesse (SIDeMaST)” has timely developed an “emergency plan” by issuing a series of informative sheets also named “vademecum” addressed to both dermatologists and patients.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results